moneyheap
IBB · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is iShares Biotechnology ETF (IBB) stock moving?
IBB has no news items or SEC filings in the 14 days before Nov 10, so this read rests on price and volume alone. Across the 14 sessions provided (Oct 22 to Nov 10), the ETF traded between $205.96 and $222.29, and the last close of $217.18 sits near the middle of that range. Two heavy-volume sessions stand out: Oct 30 (3.46M shares, intraday high $222.29) and Nov 5 (3.69M shares, close down about 5% to $209.99). The ETF recovered to $219.57 on Nov 9 and closed at $217.18 on Nov 10, and its lows since Oct 23 have been higher. With no company-level or sector catalyst in the data, the picture is a range-bound pattern with a slight upward tilt, so the outlook stays close to neutral with low confidence.
About iShares Biotechnology ETF
IBB is BlackRock's iShares Biotechnology ETF. It launched in 2001, trades on Nasdaq and holds about 250 US-listed biotech companies. It is one of the largest and oldest biotech funds, with roughly $11 billion in assets. Because it weights companies by size, large established drugmakers like Gilead, Amgen, Vertex and Regeneron make up much of the fund, and its top 10 holdings are about half of assets.
How the fund works
The fund owns the stocks in the NYSE Biotechnology Index (it used to track the Nasdaq Biotechnology Index) to match that index's returns. The index is weighted by company size, with limits on how much any one stock can make up. There's no leverage, and the annual expense ratio is about 0.44%. It pays small dividends four times a year, with a yield around 0.2%. The main risks are that it holds a single sector and that a handful of large holdings drive much of its performance.
What usually moves IBB
- Clinical trial results and FDA approvals
- Drug pricing policy and healthcare regulation
- Interest rates (which strongly affect cash-burning smaller biotechs)
- Biotech merger and acquisition activity
- Results at top holdings like Gilead, Amgen, Vertex and Regeneron